The head of the U.S. cattle business for Boehringer Ingelheim Vetmedica is Colin Meyers. Colin says the main thing the acquisition of Ft. Dodge Animal Health means to the company is that they now have a much broader range of products to offer. One product in particular, Cydectin, moves them into the anti-parasitic market with a very well recognized name.
When it comes to the cattle market he says that in the vaccine area they’ll have about 20 percent of the market and increases in other areas as well. They’ll have a larger sales and veterinarian force to reach out to customers and a bigger distribution network. They’ve spent the last three weeks bringing in new staff, distributors and others to help enable a smooth transition for customers.
You can listen to my interview with Colin below.